Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ687MR)

This product GTTS-WQ687MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ687MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3440MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ3482MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ6000MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ11225MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ14987MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ6109MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ1008MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ9653MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW